Zydus Lifesciences Shares Rise on Positive USFDA News
Zydus Lifesciences shares saw a slight increase after the USFDA's inspection at its Ahmedabad facility resulted in zero observations. The stock rose to Rs 995.50, reflecting a 0.65% gain. The company's net profit rose 3.3% year-on-year, reaching Rs 1,466.8 crore. Additionally, Zydus received approvals for multiple products, including Diltiazem Hydrochloride Tablets and Celecoxib Capsules, boosting its growth prospects. Despite a challenging year, where shares fell over 15%, analysts maintain a positive outlook, with target prices suggesting potential for recovery.
